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Molecular and functional characterization of a new 3′ end 
KIT juxtamembrane deletion in a duodenal GIST treated with 
neoadjuvant Imatinib
SUPPLEMENTARY MATERIALS
Computational details
The optimized structure of KIT was taken from our 
previous work (Tamborini et al., 2006a, 2006b; McAuliffe 
et al., 2008; Negri et al., 2009; Woodman et al., 2009; 
Conca et al., 2013). Mutations ∆559, T670I and ∆574-
580 were introduced into the wild-type structure of KIT/
imatinib complex by swapping the mutant residue into the 
specific site, according to a dedicated and well-validated 
procedure (Tamborini et al., 2006a, 2006b; McAuliffe 
et al., 2008; Negri et al., 2009; Woodman et al., 2009; 
Conca et al., 2013). Each protein/ligand system was 
relaxed in a box of TIP3P water molecules (Jorgensen 
et al., 1983). To achieve electroneutrality, a suitable 
number of neutralizing ions were added; further, the 
solution ionic strength was adjusted to the physiological 
value of 0.15 M by adding the required amounts of Na+ 
and Cl− ions. Each hydrated complex system was then 
gradually heated to 25°C and then equilibrated for 5 ns 
via molecular dynamics (MD) simulations under isobaric/
isothermal conditions (i.e., NPT ensemble). Finally, each 
MD equilibrated system was subjected to 50 ns of NPT 
MD data collection runs to estimate the corresponding 
drug/protein free energy of binding (Pierotti et al., 2010; 
Pierotti et al., 2011).
All simulations were carried out using the Pmemd 
modules of Amber 16 (Case et al., 2016).
All energetic analysis was carried out for only 
a single MD trajectory of each KIT/imatinib complex 
considered, with unbound protein and substrate snapshots 
taken from the snapshots of that trajectory. 
The affinity of the mutant KIT isoforms for imatinib 
and ATP, expressed as the value of the corresponding 
free energy of binding ∆Gbind, was estimated using the 
Molecular Mechanics/Poisson-Boltzmann Surface Area 
(MM/PBSA) method (Kollman et al., 2000, Puerotti et al., 
2011). Accordingly, the binding free energy between two 
biological entities (e.g., a drug and its protein target) in a 
solvent was obtained as the sum of the interaction energy 
between the receptor and the ligand (∆EMM), the solvation 
free energy (∆Gsol), and the conformational entropy 
contribution (−T∆S), averaged over a series of snapshots 
from the corresponding MD trajectories:
ΔGbind = ΔEMM + ΔGsolv – TΔS  (S1)
The ΔEMM term in Eq. (1) can be obtained directly from the 
molecular mechanics interaction energies as:
ΔEMM = ΔEint + ΔEvdW + ΔEele  (S2)
where ΔEint, ΔEvdW, and ΔEele are the internal, van 
der Waals and electrostatic components of the nonbonded 
interaction energy, respectively. Since in this work we 
adopted the “single trajectory protocol”, then ΔEint = 0 in 
Eq. (S2).
The second term Eq. (S1), the solvation energy ∆Gsol, 
can also be partitioned into two different contributions:
ΔGsolv = ΔGPB + ΔGNP  (S3)
The polar term of ΔGsolv, ΔGPB, was estimated by 
solving the Poisson-Boltzmann equations numerically 
and calculating the electrostatic energy according to the 
electrostatic potential. In these calculations, the interior 
and exterior dielectric constant values were set equal 
to 1 and 80, respectively. A grid spacing of 0.5 per Å, 
extending 20% beyond the dimensions of the solute, was 
employed. The value of nonpolar component of ∆Gsolv, 
∆GNP, was calculated using the following relationship 
(Sitkoff et al., 1994):
ΔGNP = γ × SA + β  (4)
in which γ = 0.00542 kcal (mol Å2)−1, β = 0.92 kcal/mol, 
and SA is the molecular surface area estimated by means of 
the MSMS software (Sanner et al., 1993).
The change in solute entropy upon association 
(−T∆S in Eq. (S1)) was evaluated using the Nmode module 
of Amber 16. The normal-node analysis was performed 
for the minimized structures of the complexes, KIT, and 
ligands using a distance-dependent dielectric constant 
ε = 4rij. In the first step of this calculation, an 8-Å sphere 
around the ligand was cut out from an MD snapshot for 
each ligand-protein complex. This value was shown to be 
large enough to yield converged mean changes in solute 
entropy. On the basis of the size-reduced snapshots of the 
complex, we generated structures of the uncomplexed 
reactants by removing the atoms of the protein and ligand, 
respectively. Each of those structures was minimized, 
using a distance-dependent dielectric constant ε = 4r, 
to account for solvent screening, and its entropy was 
calculated using classical statistical formulas and normal 
mode-analysis. To minimize the effects due to different 
conformations adopted by individual snapshots we 
averaged the estimation of entropy over 50 snapshots.
A per-residue binding free energy decomposition 
(PRBFED) was performed exploiting the MD trajectory 
of each complex. This analysis was carried out using the 
MM/GBSA approach (Tsui and Case, 2000), and was 
based on the same snapshots used in the binding free 
energy calculation.
Cloning and KIT mutants purification for 
experimental Imatinib binding studies 
∆559, T670I, and ∆574-580 mutant KIT constructs 
were produced according to the established methodology 
described by Gajiwala et al. (2009). Accordingly, a 
construct encoding an N-terminal 6X-His tag + r3c 
protease site + KIT residues 544-976 was cloned into 
the baculovirus expression vector pVL1393 (Invitrogen). 
Proteins were expressed in Sf9 cells for 48 h; cells were 
then harvested and frozen (−80°C). Cellular lysates 
were obtained by treatment with 25 mM Tris (pH 7.4), 
250 mM NaCl, 0.25 mM TCEP, and 20 mM imidazole. 
After binding to a Ni-NTA column, each protein was 
step-eluted using the same buffer employed for pellet 
lysing with 250 mM imidazole. Each peak eluted fraction 
was subjected to dialysis at 4°C for 12 h. Next, the His 
tag was cleaved with the r3C protease and removed by 
reloading the proteins on the Ni-NTA column. Each Flow-
through was collected from the column and concentrated. 
Next, each protein was feeded to a Superdex-200 column 
equilibrated in 25 mM Tris (pH 7.4), 250 mM NaCl, 
0.5 mM TCEP, and 1mM EDTA. The peak fractions were 
pooled, concentrated (up to 6 mg/ml) and quickly frozen.
Isothermal titration calorimetry (ITC) 
experiments
A solution of each purified KIT mutant protein 
(10 µM, sample cell) was titrated with 36 step-by-step 
injections (spacing 150 s) of 2 µL volume of Imatinib 
(250 µM, syringe). Solutions and buffer were degassed 
for 30 min at room temperature under stirring at 750 rpm 
prior to each experiment.
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Supplementary Figure 1: Tumor histology: (A) Histopathologic features (HE, 200×): the tumor mainly consisted of spindle cells 
exhibiting a fascicular growth pattern. (B) Immunostaining for c-KIT/CD117 (400×): most tumor cells showed membranous and/or 
cytoplamatic positivity for CD117. (C) Immunostaining for DOG1 (400×): most tumor cells showed strong immunoreactivity for DOG1.
Supplementary Figure 2: Sequencing of exon 11 of WT and mutated KIT. Top panel: comparison between exon 11 of WT and 
patient KIT. Bottom panel: Patient KIT sequence (partial in length) comprising the region encoding for the newly reported mutation Δ574-
580, sequence showing the in frame deletion mutation c1718:1739del21.
Supplementary Figure 3: Sanger sequencing of KIT exons 9, 13 and 17 hotspots (first three panels from top), and of 
PDGFRA exons 12, 14 and 18 hotspots (last three panels).
